<DOC>
	<DOCNO>NCT02907216</DOCNO>
	<brief_summary>The purpose study evaluate immunogenicity safety diphtheria , tetanus , pertussis inactivate poliovirus ( DPT-IPV ) vaccine Squarekids administer without GSK Biologicals ' liquid Rotarix ( HRV ) vaccine , healthy Japanese infant age 6 - 12 week . GSK Biologicals ' liquid HRV vaccine Rotarix license Japan since 2011 . Although concomitant administration GSK Biologicals ' DTP-IPV vaccine evaluate clinical development HRV vaccine , vaccine differ composition route administration DPT-IPV vaccine Squarekids manufacture Japan . Hence , request Japanese regulatory authority , post-licensure study evaluate immunogenicity DPT-IPV vaccine manufacture Japan co-administered liquid HRV vaccine</brief_summary>
	<brief_title>Evaluation Immunogenicity Safety Diphtheria , Tetanus , Pertussis Inactivated Poliovirus ( DPT-IPV ) Vaccine Squarekids™ Co-administered With GSK Biologicals ' Human Rotavirus ( HRV ) Vaccine Rotarix™ ( GSK444563 ) Healthy Infants</brief_title>
	<detailed_description>This study phase IV , open-label , randomise , control , multi-centric , single-country study two parallel group . Subjects co-administration group administer DPT-IPV vaccine accord 3 , 4 , 6 month schedule liquid HRV vaccine accord 2 , 3 month schedule . Subjects stagger group administer DPT-IPV vaccine accord 3 , 4.5 , 6 month schedule liquid HRV vaccine accord 2 , 3.5 month schedule . The intended duration study , per subject , 5 month . A sub-cohort subject ( HRV Immunogenicity sub-cohort ) study group include first 73 subject enrol study assess serum anti-RV IgA seropositivity Geometric Mean Concentrations ( GMC ) .</detailed_description>
	<mesh_term>Whooping Cough</mesh_term>
	<mesh_term>Tetanus</mesh_term>
	<mesh_term>Diphtheria</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Subjects ' parent ( ) / Legally Acceptable Representative ( ) [ LAR ( ) ] , opinion investigator comply requirement protocol . A male female , include , 6 12 week age time first dose HRV vaccination . Written inform consent obtain parent ( ) /LAR ( ) subject prior performing study specific procedure . Healthy subject establish medical history clinical examination enter study . Born fullterm per delivery record . Child care . Use investigational nonregistered product study vaccine within 30 day first dose study vaccine , plan use study period . Chronic administration immunosuppressant immunemodifying drug since birth . For corticosteroid , mean prednisone ( ≥ 0.5 mg/kg/day , equivalent ) . Inhaled topical steroid allow . Administration immunoglobulins and/or blood product since birth plan administration study period . Administration longacting immunemodifying drug time study period . Planned administration/administration vaccine foreseen study protocol within period start 30 day first dose HRV vaccine administration end Visit 7 , exception routinely administer vaccine like PCV , Hib , BCG , hepatitis B , meningococcal vaccine inactivate influenza vaccine , allow time study , administer site different site use administer DPTIPV vaccine . Concurrently participate another clinical study , time study period , subject expose investigational noninvestigational vaccine/product . Uncorrected congenital malformation gastrointestinal tract would predispose Intussusception ( IS ) . History IS . Family history congenital hereditary immunodeficiency . Any confirm suspected immunosuppressive immunodeficient condition , base medical history physical examination . Major congenital defect serious chronic illness . Previous vaccination rotavirus , diphtheria , tetanus , pertussis and/ poliovirus . Previous confirm occurrence RV GE , diphtheria , tetanus , pertussis , and/ polio disease . GE within 7 day precede HRV vaccine administration . History reaction hypersensitivity likely exacerbate component HRV DPTIPV vaccine . Hypersensitivity latex . History neurological disorder seizure . History SCID . Acute disease and/or fever time enrollment . Fever define temperature ≥ 37.5°C /99.5°F oral , axillary tympanic setting , ≥ 38.0°C /100.4°F rectal setting . Subjects minor illness without fever may enrol discretion investigator .</criteria>
	<gender>All</gender>
	<minimum_age>6 Weeks</minimum_age>
	<maximum_age>12 Weeks</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>Healthy Japanese infant</keyword>
	<keyword>Safety</keyword>
	<keyword>Diphtheria , Tetanus , Pertussis Inactivated Poliovirus ( DPT-IPV ) vaccine</keyword>
	<keyword>Vaccination</keyword>
	<keyword>Oral HRV liquid vaccine</keyword>
	<keyword>Immunogenicity</keyword>
</DOC>